NECT (Nifurtimox-Eflornithine Combination Therapy), a new treatment option against sleeping sickness, a fatal disease which threatens 60 million people across sub-Saharan Africa, has been added to the Essential Medicines List (EML) of the World Health Organization (WHO) based on the application submitted by the non-profit Drugs for Neglected Diseases initiative (DNDi) and supported by Epicentre and Medecins Sans Frontieres (MSF). More at...
Most new college graduates say they're ready for the "real world." But are they ready for the world of health insurance? More at...
NECT (Nifurtimox-Eflornithine Combination Therapy), a new treatment option for sleeping sickness, a fatal disease that threatens 60 million people across sub-Saharan Africa, has been added to the Essential Medicines List (EML) of the World Health Organization (WHO). More at...
Officials in the Obama administration are seeking to reassure an edgy public about a potential swine flu outbreak, stressing the need for patience and preparedness, not panic. More at...
We started our discussion about restless legs syndrome (RLS) in my recent blog, so let’s continue where we left off. Mild symptoms of RLS occur in 5-15% of the general population, which makes it the second or third most common sleep disorder. Of these cases, only about 2-3% are considered clinically severe enough to require treatment. It appears to occur more commonly in females and can even affect children. Due... More at...
New research suggests that patients newly diagnosed with obstructive sleep apnea (OSA) who use a short-course of the sleep aid, eszopiclone, when beginning continuous positive airway pressure (CPAP) therapy, are more adherent with therapy in six months. The findings were presented at the American Thoracic Society's International Conference in San Diego on May 17. OSA is a common disorder that leads to multiple adverse effects on health and quality of life. More at...
Subscribe to:
Posts (Atom)
